

# 1 **COVID-19 Variant Detection with a High-Fidelity CRISPR-Cas12 Enzyme**

2 Clare L. Fasching<sup>1\*</sup>, Venice Servellita<sup>2,3\*</sup>, Bridget McKay<sup>1</sup>, Vaishnavi Nagesh<sup>1</sup>, James  
3 P. Broughton<sup>1</sup>, Noah Brazer<sup>2,3</sup>, Baolin Wang<sup>2,3</sup>, Alicia Sotomayor-Gonzalez<sup>2,3</sup>, Kevin  
4 Reyes<sup>2,3</sup>, Jessica Streithorst<sup>2,3</sup>, Rachel N. Deraney<sup>1</sup>, Emma Stanfield<sup>1</sup>, Carley G.  
5 Hendriks<sup>1</sup>, Steve Miller<sup>2,3</sup>, Jesus Ching<sup>1</sup>, Janice S. Chen<sup>1†</sup>, Charles Y. Chiu<sup>2,3,4†</sup>

6

7 <sup>1</sup> Mammoth Biosciences, Inc., Brisbane, CA, USA.

8 <sup>2</sup> Department of Laboratory Medicine, University of California San Francisco, San  
9 Francisco, CA, USA.

10 <sup>3</sup> UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.

11 <sup>4</sup> Department of Medicine, Division of Infectious Diseases, University of California San  
12 Francisco, San Francisco, CA, USA.

13 \*These authors contributed equally

14 †Co-corresponding authors

15

## 16 **Abstract**

17 Laboratory tests for the accurate and rapid identification of SARS-CoV-2 variants have  
18 the potential to guide the treatment of COVID-19 patients and inform infection control  
19 and public health surveillance efforts. Here we present the development and validation  
20 of a COVID-19 variant DETECTR<sup>®</sup> assay incorporating loop-mediated isothermal  
21 amplification (LAMP) followed by CRISPR-Cas12 based identification of single  
22 nucleotide polymorphism (SNP) mutations in the SARS-CoV-2 spike (S) gene. This  
23 assay targets the L452R, E484K, and N501Y mutations associated with nearly all

24 circulating viral lineages. In a comparison of three different Cas12 enzymes, only the  
25 newly identified enzyme CasDx1 was able to accurately identify all three targeted SNP  
26 mutations. We developed a data analysis pipeline for CRISPR-based SNP identification  
27 using the assay from 91 clinical samples (Ct < 30), yielding an overall SNP concordance  
28 and agreement with SARS-CoV-2 lineage classification of 100% compared to viral  
29 whole-genome sequencing. These findings highlight the potential utility of CRISPR-  
30 based mutation detection for clinical and public health diagnostics.

31

## 32 **Introduction**

33 The emergence of new SARS-CoV-2 variants threatens to substantially prolong the  
34 COVID-19 pandemic. SARS-CoV-2 variants, especially Variants of Concern (VOCs) (1,  
35 2), have caused resurgent COVID-19 outbreaks in the United States (2-5) and  
36 worldwide (1, 6, 7), even in populations with a high proportion of vaccinated individuals  
37 (8-11). Mutations in the spike protein, which binds to the human ACE2 receptor, can  
38 render the virus more infectious and/or more resistant to antibody neutralization,  
39 resulting in increased transmissibility (12), and/or escape from immunity, whether  
40 vaccine-mediated or naturally acquired immunity (13, 14). Variant identification can also  
41 be clinically significant, as some mutations substantially reduce the effectiveness of  
42 available monoclonal antibody therapies for the disease (15).

43

44 Tracking the evolution and spread of SARS-CoV-2 variants in the community is critical  
45 to inform public policy regarding testing and vaccination, as well as guide contact  
46 tracing and containment effects during local outbreaks (16, 17). Virus whole-genome

47 sequencing (WGS) and single nucleotide polymorphism (SNP) genotyping are  
48 commonly used to identify variants Harper, 2021 #100;Oude Munnink, 2021 #99}, but  
49 can be limited by long turnaround times and/or the requirement for bulky and expensive  
50 laboratory instrumentation. Diagnostic assays based on clustered interspaced short  
51 palindromic repeats (CRISPR) (18) have been developed for rapid detection of SARS-  
52 CoV-2 in clinical samples (13, 19-22),, and a few have obtained Emergency Use  
53 Authorization (EUA) by the US Food and Drug Administration (FDA) (23, 24). Some  
54 advantages of these assays for use in laboratory and point of care settings include low  
55 cost, minimal instrumentation, and a sample-to-answer turnaround time of under 2  
56 hours (19, 22, 25, 26).

57  
58 Here we present the development of a CRISPR-based COVID-19 variant DETECTR<sup>®</sup>  
59 assay (henceforth abbreviated as DETECTR<sup>®</sup> assay) for the detection of SARS-CoV-2  
60 mutations and evaluate its performance on 91 clinical samples using WGS as a  
61 comparator method (**Fig. 1A**). The assay combines RT-LAMP pre-amplification followed  
62 by fluorescent detection using a CRISPR-Cas12 enzyme. We perform a comparative  
63 evaluation of multiple candidate Cas12 enzymes and demonstrate that robust assay  
64 performance depends on the specificity of the newly identified CRISPR-Cas12 enzyme  
65 called CasDx1 in identifying three key SNP mutations of functional relevance in the  
66 spike protein, N501Y, L452R, and E484K (27).

67

## 68 **Results**

### 69 **Identifying the optimal CRISPR-Cas12 enzyme for SNP detection**

70 To determine the optimal Cas12 enzyme for SNP detection, we evaluated three  
71 different CRISPR-Cas effectors with trans-cutting activity: LbCas12a, AsCas12a, and a  
72 novel Cas12 enzyme called CasDx1. We initially screened guide RNAs (gRNAs) with  
73 CasDx1 and LbCas12a for activity on synthetic gene fragments encoding regions of the  
74 SARS-CoV-2 S-gene with either wild-type (WT) or mutant (MUT) sequences at amino  
75 acid positions 452, 484, and 501 (**Fig. 1B-C**). From this initial activity screen, we  
76 identified the top-performing gRNAs for each S-gene variant encoding either L452R,  
77 E484K or N501Y (**Fig. 1D**). Further evaluation of these guides using CasDx1,  
78 LbCas12a and AsCas12a with their cognate gRNAs on synthetic gene fragments  
79 revealed differences in SNP differentiation capabilities, with CasDx1 showing the  
80 clearest SNP differentiation between wild-type (WT) and mutant (MUT) sequences for  
81 all three S-gene variants (**Fig. 1D and Fig. S1A**). In comparison, LbCas12a was  
82 capable of differentiating SNPs at positions 452 and 484, but not 501, whereas  
83 AsCas12a was only able to differentiate the SNP at position 452 (**Fig. 1D and Fig.**  
84 **S1A**).

85

86 We next tested SNP differentiation capabilities on heat-inactivated viral cultures using  
87 the full DETECTR<sup>®</sup> assay, consisting of RNA extraction, multiplexed RT-LAMP  
88 amplification (**Fig. 1C**), and CRISPR-Cas12 detection with guide RNAs targeting part of  
89 the spike receptor-binding domain (RBD) (**Fig. 1B**). The LAMP primer design  
90 incorporated two sets of six primers each, with both sets generating overlapping spike  
91 RBD amplicons that spanned the L452R, E484K, and N501Y mutations. We chose to  
92 adopt a redundant LAMP design for two reasons: first, this approach was shown to

93 improve detection sensitivity in initial experiments; second, we sought to increase assay  
94 robustness given the continual emergence of escape mutations in the spike RBD  
95 throughout the course of the pandemic (13). The tested viral cultures included an  
96 ancestral SARS-CoV-2 lineage (WA-1) containing the wild-type spike protein (D614)  
97 targeted by the approved mRNA (Pfizer and Moderna) (28, 29) and DNA adenovirus  
98 vector (Johnson and Johnson) (30) vaccines, variants being monitored (VBM) that  
99 were previously classified as VOCs or variants of interest (VOIs), including Alpha  
100 (B.1.1.7), Beta (B.1.351), Gamma (P.1), Epsilon (B.1.427 and B.1.429), Kappa  
101 (B.1.617.1), and Zeta (P.2) lineages, and the current VOC Delta (B.1.617.2) lineage  
102 (31). Heat-inactivated viral culture samples representing the seven SARS-CoV-2  
103 lineages were quantified by digital droplet PCR across a 4-log dynamic range and used  
104 to evaluate the analytical sensitivity of the pre-amplification step. RT-LAMP amplification  
105 was evaluated using six replicates from each viral culture. We observed consistent  
106 amplification for all seven SARS-CoV-2 lineages with 10,000 copies of target input per  
107 reaction (200,000 copies/mL) (**Fig. 1E**), which is comparable to the target input of  
108 >200,000 copies/mL viruses (<30 Ct value) required for sequencing workflows used in  
109 SARS-CoV-2 variant surveillance (32, 33).

110

111 To evaluate the specificity of the different Cas12 enzymes, amplified material from each  
112 viral culture was pooled and the SNPs resulting in the L452R, E484K and N501Y  
113 mutations were detected using CasDx1, LbCa12a and AsCas12a. Similar to the results  
114 found using gene fragments, CasDx1 correctly identified the wild-type (WT) and  
115 mutational (MUT) targets at positions 452, 484 and 501 in each LAMP-amplified, heat-

116 inactivated viral culture (**Fig. 1F and Fig. S1B**). In comparison, LbCas12a was capable  
117 of differentiating WT from MUT at position 501 on LAMP-amplified viral cultures but  
118 showed much higher background for the WT target at position 452 and higher  
119 background for both WT and MUT targets at position 484 for (**Fig. 1F and Fig. S1B**).  
120 Additionally, AsCas12a was able to differentiate WT from MUT targets at position 452  
121 albeit with substantial background but was unable to differentiate WT from MUT targets  
122 at positions 484 and 501 (**Fig. 1F and Fig. S1B**). From these data, we concluded that  
123 CasDx1 would provide more consistent and accurate calls for the L452R, E484K and  
124 N501Y mutations. We thus proceeded to further develop the assay using only the high-  
125 fidelity CasDx1 enzyme.  
126



128 **Fig. 1. Design and Workflow for the DETECTR<sup>®</sup> assay.** (A) Workflow comparison  
129 between the DETECTR<sup>®</sup> assay and SARS-CoV-2 whole-genome sequencing (WGS).  
130 (B) Schematic of CRISPR-Cas gRNA design for SARS-CoV-2 S gene mutations. (C)  
131 Schematic of multiplexed RT-LAMP primer design showing the SARS-CoV-2 S gene  
132 mutations and gRNA positions. (D) Heat map comparison of three different Cas12  
133 enzymes tested using 10 nM PCR-amplified synthetic gene fragments. (E) Dot plot  
134 showing the number (n=6) of positive replicates across a 4-log dynamic range of the  
135 RT-LAMP products (F) Heat map comparison of end-point fluorescence of three  
136 different Cas12 enzymes tested against heat-inactivated viral cultures. Replicates (n=6)  
137 generated using RT-LAMP were pooled and CRISPR-Cas12 reactions were then run in  
138 triplicate (n=3).

139

#### 140 **Development of a data analysis pipeline for calling COVID-19 variant SNPs with** 141 **the DETECTR<sup>®</sup> assay**


142 To develop a data analysis pipeline for calling SARS-CoV-2 SNP mutations and assign  
143 lineage classifications with the DETECTR<sup>®</sup> assay (**Fig. 2A-B**), we first used data  
144 collected from SNP synthetic gene fragment controls (n=279) that included all  
145 mutational combinations of 452, 484 and 501 (see Methods). Based on the control  
146 sample data, we generated allele discrimination plots (34, 35) to define boundaries that  
147 separate the WT and MUT signals (**Fig. S4A**). Clear differentiation between WT and  
148 MUT signals was observed when plotting the ratio against the average of the WT and  
149 MUT transformed values on a mean average (MA) plot (34, 35) (**Fig. S4B**), with 100%  
150 concordance for SNP identity at positions 452, 484, and 501 for the control samples.



151

152 **Performance evaluation of the DETECTR<sup>®</sup> assay using clinical samples**

153 Next, we assembled a blinded dataset consisting of 93 COVID-19 positive clinical  
154 samples (previously analyzed by viral WGS) and the SNP controls run in parallel. These  
155 samples were extracted, amplified in triplicate RT-LAMP reactions (**Fig. S2**), and  
156 processed further as triplicate CasDx1 reactions for each LAMP replicate (**Fig. S3**). A  
157 total of nine replicates were thus generated for each sample to detect WT or MUT SNPs  
158 at positions 452, 484, and 501. The DETECTR<sup>®</sup> data analysis pipeline was then applied  
159 to each sample to provide a final lineage categorization (**Fig. 2A-C**). For a biological  
160 RT-LAMP replicate to be designated as either WT or MUT, the same call needed to be  
161 made from all three technical CasDx1 replicates (**Fig. S5A**). A final SNP mutation call  
162 was made based on  $\geq 1$  of the same calls from the three biological replicates, with  
163 replicates that were designated as a No Call ignored (**Fig. S5A-C**). After excluding two  
164 samples that were considered invalid because the fluorescence intensity from RT-LAMP  
165 amplification did not reach a pre-established threshold determined using receiver-  
166 operator characteristic (ROC) curve analysis (**Fig. S2 and Fig. S6**), we evaluated a total  
167 of 807 CasDx1 signals from the 91 remaining clinical samples, generating up to 9  
168 replicates for each clinical sample (**Fig. S5B**). Differentiation of WT and MUT signals  
169 according to the allele discrimination plots was more pronounced at positions 484 and  
170 501 than position 452 (**Fig. S4**), whereas the MA plots showed clear separation of WT  
171 and MUT calls for all three positions (**Fig. 3A and Fig. S4**). The variant calls made on  
172 each sample were consistent with the difference in median values of the log-  
173 transformed signals as determined using the data analysis pipeline (**Fig. S7**).



175 **Fig. 2. DETECTR<sup>®</sup> data analysis pipeline for SARS-CoV-2 SNP mutation calling.**

176 (A) Interpretation table summarizing the SARS-CoV-2 mutations in this study  
177 associated with the corresponding lineage classification. (B) Schematic of data analysis  
178 pipeline describing the RT-LAMP QC and subsequent CasDx1 signal scaling. The  
179 scaled signals were compared across SNPs and the calls were made for each RT-  
180 LAMP replicate. The combined replicate calls defined the mutation call, which informed  
181 the final lineage classification. (C) Three representative clinical samples of different  
182 SARS-CoV-2 lineages depict the workflow of the DETECTR<sup>®</sup> assay. Raw fluorescence  
183 curves of each sample run in RT-LAMP amplification and subsequent triplicate  
184 DETECTR<sup>®</sup> reactions targeting both WT and MUT SNPs for L452(R), E484(K), and  
185 N501(Y). Box plot visualization of the end point fluorescence in DETECTR<sup>®</sup> across each  
186 SNP for the three representative clinical samples. Calls were made for each SNP by  
187 evaluating the median values of the DETECTR<sup>®</sup> calls and overall calls through the  
188 LAMP replicates, and given a designation of WT, MUT, or NoCall. Final calls are made  
189 on the lineage determined by each SNP. Blue represents WT and green represents  
190 MUT, with RT-LAMP replicates (n = 3), CasDx1 replicates (n = 3 per LAMP replicate)  
191 and shading around kinetic curves indicates  $\pm 1.0SD$ .

192


193 We then unblinded the viral WGS results to evaluate the accuracy of the DETECTR<sup>®</sup>  
194 assay for SNP calls and lineage classification. There were 14 discordant SNP calls out  
195 of 272 (94.9% SNP concordance) distributed among 11 clinical samples out of 91 (Fig.  
196 **S8A-C**). Among the 11 discordant samples, one sample (COVID-31) was designated a  
197 'no call' at position 452 by viral WGS and thus lacked a comparator, two samples were

198 designated a 'no call' due to flat WT and MUT curves (COVID-41 and COVID-73), four  
199 samples had similar WT and MUT curve amplitudes, suggesting a mixed population  
200 (COVID-03, COVID-56, COVID-61 and COVID-81) (**Fig. S8A**), and four samples had  
201 SNP assignments discordant with those from viral WGS (COVID-12, COVID-13,  
202 COVID-20 and COVID-63) (**Fig. S8A**).

203  
204 Given that the comparison data had been collected over an extended time period, we  
205 surmised that sample stability issues arising from aliquoting and multiple freeze-thaw  
206 cycles may have accounted for the observed discrepancies. To further investigate this  
207 possibility, the 11 discordant clinical samples were re-extracted from original respiratory  
208 swab matrix and re-analyzed by running both viral WGS and the DETECTR<sup>®</sup> assay in  
209 parallel. Re-testing of the samples resulted in nearly complete agreement between the  
210 two methods, with the exception of two SNPs that were identified as E484Q in two  
211 samples by WGS but were incorrectly called E484 (WT) by the DETECTR<sup>®</sup> assay (**Fig.**  
212 **3B-C and Fig. S8D**). Thus, based on discrepancy testing, the positive predictive  
213 agreement (PPA) between the DETECTR<sup>®</sup> assay and viral WGS at all three WT and  
214 MUT SNP positions was 100% (272 of 272,  $p < 2.2e-16$  by Fisher's Exact Test) (**Fig.**  
215 **3D**). The corresponding negative predictive agreement (NPA) was 91.4% as the E484Q  
216 mutation for two SNPs was incorrectly classified as WT. Nevertheless, the final viral  
217 lineage classification for the 91 samples after discrepancy testing showed 100%  
218 agreement with viral WGS (**Fig. 3D and Table S1**).

219

220



221

222 **Fig. 3. Evaluation of the DETECTR® assay compared to SARS-CoV-2 Whole-**

223 **Genome Sequencing. (A) MA-plots showing CasDx1 SNP detection replicates (n =**

224 807) for each SARS-CoV-2 mutation across 91 clinical samples. WT is denoted by blue  
225 dots, MUT is denoted by green dots, NoCall is denoted by orange dots and NTC is  
226 denoted by grey dots. **(B)** Alignment of final mutation calls comparing the DETECTR<sup>®</sup>  
227 and SARS-CoV-2 WGS assay results across 91 clinical samples after discordant  
228 samples (indicated by red asterisk) were resolved. **(C)** Final lineage classification on  
229 each clinical sample by the DETECTR<sup>®</sup> assay compared to the SARS-CoV-2 lineage  
230 determined by viral WGS. **(D)** Final Positive Predictive Agreement (PPA), Negative  
231 Predictive Agreement (NPA) and concordance values for each WT and MUT SNP from  
232 the evaluation of the DETECTR<sup>®</sup> assay against the SARS-CoV-2 WGS comparator  
233 assay after discordant samples were resolved.

234

## 235 **Discussion**

236 In this study, we developed a CRISPR-based DETECTR<sup>®</sup> assay for the detection of  
237 SARS-CoV-2 variants. We evaluated three CRISPR-Cas12 enzymes, two commercially  
238 available (LbCas12a from NEB and AsCas12a from IDT) and one proprietary (CasDx1  
239 from Mammoth Biosciences). Based on a head-to-head comparison of these enzymes,  
240 we observed clear differences in performance, with CasDx1 demonstrating the highest  
241 fidelity as the only enzyme able to reliably detect all three of the targeted SNPs. A data  
242 analysis pipeline was developed to differentiate between WT and MUT signals with the  
243 DETECTR<sup>®</sup> assay, yielding an overall SNP concordance of 100% (272/272 total SNP  
244 calls) and 100% agreement with lineage classification compared to viral WGS. Taken  
245 together, these findings show robust agreement between the DETECTR<sup>®</sup> assay and  
246 viral WGS for identification of SNP mutations and variant categorization. Thus, the

247 DETECTR<sup>®</sup> assay provides a faster and simpler alternative to sequencing-based  
248 methods for COVID-19 variant surveillance.

249

250 Our results show that the choice of Cas enzyme is important to maximize the accuracy  
251 of CRISPR-based diagnostic assays and may need to be tailored to the site that is  
252 being targeted. As currently configured with only three SNP targets, the DETECTR<sup>®</sup>  
253 assay cannot resolve individual major variants, except for Alpha. However, given the  
254 rapid emergence and dynamic shifts in the distribution of variants over time (13), it is  
255 likely that tracking of key mutations, several of which are suspected to arise by  
256 convergent evolution (36), rather than tracking of variants, will be critical for surveillance  
257 as the pandemic continues. Furthermore, we also develop a data analysis pipeline for  
258 CRISPR-based SNP calling that can readily incorporate additional targets and offers a  
259 blueprint for automated interpretation of fluorescent signals that will become more  
260 complex as the degree of multiplexing increases.

261

262 Although CRISPR-based diagnostic assays have been previously demonstrated for the  
263 detection of SARS-CoV-2 variants, these studies have limitations in coverage of  
264 circulating lineages and in the extent of clinical sample evaluation. For example, the  
265 miSHERLOCK variant assay uses LbCas12a (NEB) to detect N501Y, E484K and  
266 Y144Del covering eight lineages (WA-1, Alpha, Beta, Gamma, Eta, Iota, Mu and Zeta)  
267 and was tested only on contrived samples (RNA spiked into human saliva) (20).

268 Additionally, the SHINEv2 assay uses LwaCas13a to detect 69/70Del, K417N/T, L452R  
269 and 156/157Del + R158G covering eight lineages (WA-1, Alpha, Beta, Gamma, Delta,

270 Epsilon, Kappa and Mu) and was tested with only the 69/70Del gRNAs on 20 Alpha-  
271 positive NP clinical samples (37). In comparison, the DETECTR<sup>®</sup> assay presented here  
272 uses CasDx1 to detect N501Y, E484K and L452R covering 11 lineages (WA-1, Alpha,  
273 Beta, Gamma, Delta, Epsilon, Eta, Iota, Kappa, Mu and Zeta) and 91 clinical samples  
274 representing seven out of the 11 lineages were tested with successful detection of all 7.

275

276 Some limitations of our study are as follows. First, as previously mentioned, the  
277 DETECTR<sup>®</sup> assay currently detects only three SNPs, which may not provide enough  
278 resolution to identify a specific lineage. Second, we observed variable performance of  
279 the assay in SNP discrimination, with more potential overlap in the calls between WT  
280 and MUT for the 452 position than for the other two sites, increasing the risk of  
281 misidentification. Third, our 484 gRNA was unable to differentiate E484Q from E484  
282 (WT) in clinical samples, which could impact the accuracy of lineage classification (we  
283 note, however, that the E484Q mutation corresponds to a different nucleotide position in  
284 the affected 484 codon than the E484K mutation). These first 3 limitations could  
285 potentially be addressed by the incorporation of additional gRNAs to the assay to  
286 provide specific and redundant coverage and to improve identification of specific  
287 lineages. Fourth, due to the multiplexed S-gene LAMP primer design, the limit of  
288 detection of the DETECTR<sup>®</sup> assay is higher than our previously published SARS-CoV-2  
289 DETECTR<sup>®</sup> assay (19), and thus only clinical samples with a Ct < 30 were tested in our  
290 study. Incorporation of the N-gene target as a separate reaction in the assay may be  
291 necessary for covering the dynamic range of COVID-19 positive samples if  
292 simultaneous detection and SNP/variant identification is desired. Finally, the current



293 study focuses on the development and validation of a variant DETECTR<sup>®</sup> assay using  
294 conventional laboratory equipment. Future work will involve implementation onto  
295 automated, portable systems for use in point of care settings.

296

297 In the near term, we suggest the use of the DETECTR<sup>®</sup> assay as an initial screen for  
298 the presence of a rare or novel variant (e.g., carrying both L452R and E484K or carrying  
299 all three SNPs) that could be reflexed to viral WGS. As the sequencing capacity for  
300 most clinical and public health laboratories is limited, the DETECTR<sup>®</sup> assay would thus  
301 enable rapid identification of variants circulating in the community to support outbreak  
302 investigation and public health containment efforts. Furthermore, identification of  
303 specific mutations associated with neutralizing antibody evasion, such as E484K (14),  
304 could inform patient care with regards to the use of monoclonal antibodies that remain  
305 effective in treating the infection (15). As the virus continues to mutate and evolve, the  
306 DETECTR<sup>®</sup> assay can be readily reconfigured by validating new gRNAs and pre-  
307 amplification LAMP primers and gRNAs that target emerging mutations with clinical and  
308 epidemiological significance. For example, we postulate that the newly emerging  
309 Omicron variant, containing at least 30 mutations in the spike protein and 11 mutations  
310 in the spike RGD region targeted by the assay, could be detected by increasing  
311 degeneracy in the LAMP primers and adding at least one gRNA to be able to distinguish  
312 this variant from the others. Over the longer term, a validated CRISPR assay that  
313 combines SARS-CoV-2 detection with variant identification would be useful as a tool for  
314 simultaneous COVID-19 diagnosis in individual patients and surveillance for infection  
315 control and public health purposes.

## 316 **Materials and Methods**

317

### 318 **Human Sample Collection and Ethics Statement**

319 Remnant nasopharyngeal and/or oropharyngeal (NP/OP) samples and plasma  
320 samples from laboratory confirmed SARS-CoV-2 positive patients were retrieved from  
321 the UCSF Clinical Laboratories and stored in a biorepository until processed. Remnant  
322 sample biobanking was performed with a waiver of consent and according to no-subject  
323 contact study protocols approved by the UCSF Institutional Review Board (protocol  
324 numbers 10-01116 and 11-05519).

325

### 326 **Synthetic Gene Fragments**

327 Wild-type (WT) and mutant (MUT) synthetic gene fragments (Twist) were PCR amplified  
328 using NEB 2x Phusion Master Mix following the manufacturer's protocol. The amplified  
329 product was cleaned using AMPure XP beads following manufacturers protocol at a  
330 0.7x concentration. The product was eluted in nuclease-free water and normalized to 10  
331 nM. All nucleic acids used in this study are summarized in **Table S2**.

332

### 333 **Clinical sample acquisition and extraction**

334 De-identified residual SARS-CoV-2 RT-PCR positive nasopharyngeal and/or  
335 oropharyngeal (NP/OP) swab samples in universal transport media (UTM) or viral  
336 transport media (VTM) were obtained from the UCSF Clinical Microbiology Laboratory.  
337 All samples were stored in a biorepository according to protocols approved by the

338 UCSF Institutional Review Board (protocol number 10-01116, 11-05519) until  
339 processed.

340

341 All NP/OP swab samples obtained from the UCSF Clinical Microbiology Laboratory  
342 were pretreated with DNA/RNA Shield (Zymo Research, # R1100-250) at a 1:1 ratio.

343 The Mag-Bind Viral DNA/RNA 96 kit (Omega Bio-Tek, # M6246-03) on the KingFisher

344 Flex (Thermo Fisher Scientific, # 5400630) was used for viral RNA extraction using an

345 input volume of 200  $\mu$ l of diluted NP/OP swab sample and an elution volume of 100  $\mu$ l.

346 The Taqpath™ COVID-19 RT-PCR kit (Thermo Fisher Scientific) was used to determine  
347 the N gene cycle threshold values.

348

#### 349 **Heat-inactivated culture acquisition and extraction**

350 Heat-inactivated cultures of SARS-CoV-2 Variants Being Monitored (VBM), Variants of

351 Concern (VOC) or Variants of Interest (VOI) were provided by the California Department

352 of Public Health (CDPH).

353

354 RNA from heat-inactivated SARS-CoV-2 VBM/VOC/VOI isolates were extracted using

355 the EZ1 Virus Mini Kit v2.0 (Qiagen, # 955134) on the EZ1 Advanced XL (Qiagen, #

356 9001875) according to the manufacturer's instructions. For each culture, six replicate

357 LAMP reactions were pooled into a single sample. DETECTR® was performed on a

358 1:10 dilution of the 10,000 cp/rxn LAMP amplification products.

359

#### 360 **COVID-19 variant DETECTR® assay**

361 Two LAMP primer sets, each containing 6 primers, were designed to target the L452R,  
362 E484K and N501Y mutations in the SARS-CoV-2 Spike (S) protein (Supplemental  
363 Table). Sets of LAMP primers were designed from a 350 bp target sequence spanning  
364 the 3 mutations using Primer Explorer V5 (<https://primerexplorer.jp/e/>). Candidate  
365 primers were manually evaluated for inclusion using the OligoCalc online  
366 oligonucleotide properties calculator (38) while ensuring that there was no overlap with  
367 either primers from the other set or guide RNA target regions that included the L452R,  
368 E484K, and N501Y mutations.

369

370 Multiplexed RT-LAMP was performed using a final reaction volume of 50  $\mu$ l, which  
371 consisted of 8  $\mu$ l RNA template, 5  $\mu$ l of L452R primer set (Eurofins Genomics), 5  $\mu$ l of  
372 E484K/N501Y primer set, 17  $\mu$ l of nuclease-free water, 1  $\mu$ l of SYTO-9 dye  
373 (ThermoFisher Scientific), and 14  $\mu$ l of LAMP mastermix. Each of the primer sets  
374 consisted of 1.6  $\mu$ M each of inner primers FIP and BIP, 0.2  $\mu$ M each of outer primers F3  
375 and B3, and 0.8  $\mu$ M each of loop primers LF and LB). The LAMP mastermix contained 6  
376 mM of  $MgSO_4$ , isothermal amplification buffer at 1X final concentration, 1.5 mM of dNTP  
377 mix (NEB), 8 units of Bst 2.0 WarmStart DNA Polymerase (NEB), and 0.5  $\mu$ l of  
378 WarmStart RTx Reverse Transcriptase (NEB). Plates were incubated at 65°C for 40  
379 minutes in a real-time Quantstudio™ 5 PCR instrument. Fluorescent signals were  
380 collected every 60 seconds

381

382 40nM CasDx1 (Mammoth Biosciences), LbCas12a (EnGen® Lba Cas12a, NEB) or  
383 AsCas12a (Alt-R® A.s. Cas12a, IDT) protein targeting the WT or MUT SNP at L452(R),

384 E484(K) or N501(Y) was incubated with 40nM gRNA in 1X buffer (MBuffer3 for CasDx1,  
385 NEBuffer r2.1 for LbCas12a and AsCas12a) for 30 min at 37°C. Dx1 gRNAs were used  
386 with both CasDx1 and LbCas12a, whereas AsCas12a gRNAs were used with  
387 AsCas12a (**Table S2**). 100nM ssDNA reporter (/5Alex594N/TTATTATT/3IAbRQSp/  
388 IDT) was added to the RNA-protein complex. 18µL of this DETECTR® master mix was  
389 combined with 2 µL target amplicon. The DETECTR® assays were monitored for 30 min  
390 at 37°C in a plate reader (Tecan).

391

### 392 **Digital PCR**

393 Samples were evaluated at 3 dilutions (1:100; 1:1,000; and 1:10,000) using the ApexBio  
394 Covid-19 Multiplex Digital PCR Detection Kit (Stilla Technologies) according to the  
395 manufacturer's protocol. The controls (positive and negative provided by UCSF, the Kit  
396 Controls, and an internal control) were run with the samples in duplicate. The dilutions  
397 were used to determine the most accurate concentration which was determined from  
398 the N gene concentration.

399

### 400 **Sequencing methods**

401 Complementary DNA (cDNA) synthesis from RNA via reverse transcription and tiling  
402 multiplexed amplicon PCR were performed using SARS-CoV-2 primers version 3  
403 according to a published protocol (39). Libraries were constructed by ligating adapters  
404 to the amplicon products using NEBNext Ultra II DNA Library Prep Kit for Illumina (New  
405 England Biolabs, # E7645L), barcoding using NEBNext Multiplex Oligos for Illumina  
406 (New England Biolabs, # E6440L), and purification with AMPure XP (Beckman-Coulter,

407 # 63880). Final pooled libraries were sequenced on either Illumina NextSeq 550 or  
408 Novaseq 6000 as 1x300 single-end reads (300 cycles).  
409  
410 SARS-CoV-2 viral genome assembly and variant analyses were performed using an in-  
411 house bioinformatics pipeline. Briefly, sequencing reads generated by Illumina  
412 sequencers (NextSeq 550 or NovaSeq 6000) were demultiplexed and converted to  
413 FASTQ files using bcl2fastq (v2.20.0.422). Raw FASTQ files were first screened for  
414 SARS-CoV-2 sequences using BLASTn (BLAST+ package 2.9.0) alignment against the  
415 Wuhan-Hu-1 SARS-CoV-2 viral reference genome (NC\_045512). Reads containing  
416 adapters, the ARTIC primer sequences, and low-quality reads were filtered using  
417 BBDuk (version 38.87) and then mapped to the NC\_045512 reference genome using  
418 BMap (version 38.87). Variants were called with CallVariants and a depth cutoff of 5  
419 was used to generate the final assembly. Pangolin software (version 3.0.6) (40, 41) was  
420 used to identify the lineage. Using a custom in-house script, consensus FASTA files  
421 generated by the genome assembly pipeline were scanned to confirm L452R, E484K,  
422 and N501Y mutations.

423

#### 424 **Discordant sample retesting**

425 Eleven samples were re-extracted as described above for the NP/OP swab samples  
426 and evaluated by viral WGS as described above. The samples were then thawed (XXX  
427 freeze/thaws) and amplified using the LAMP protocol described above and evaluated  
428 using the DETECTR<sup>®</sup> assay as described above.

429

430 **DETECTR<sup>®</sup> data analysis pipeline**

431 Quality Control Metric for the LAMP Reaction

432 Prior to processing DETECTR<sup>®</sup> data from the clinical samples, we collected data  
433 indicating the success or failure of the samples to amplify in the LAMP reaction. The  
434 absolute truth was based on visual inspection of LAMP curves This absolute truth was  
435 used to develop thresholds for the LAMP reactions. The positive and negative controls  
436 from the LAMP reactions were used to derive the thresholds to qualify the samples. Two  
437 sets of thresholds were used: time threshold and fluorescence rate threshold. The  
438 positive LAMP controls were assumed to represent an ideal sample and displayed a  
439 classic sigmoidal rise of fluorescence over time and the NTC represented the  
440 background fluorescence. It was hypothesized that a sample will ideally have positive  
441 control like fluorescence kinetics. However due to the presence of high background in  
442 some samples, a mean value between controls for each plate was chosen as threshold.  
443 After this, the fluorescence values at a time threshold of 18 minutes were collected. The  
444 time point is of importance here to rule out those samples that would amplify closer to  
445 the endpoint, signifying the LAMP intermediates to be the majority contributors of the  
446 rise in the signal and not the actual sample itself. A score was assigned for each sample  
447 which was calculated as a ratio of rate of fluorescence rate threshold to the rate of  
448 fluorescence value at 18 minutes for each sample. The hypothesis is that if this ratio of  
449 rate of fluorescence between controls and samples is less than 1, then samples have  
450 failed to reach the minimum fluorescence required to be called out as amplified and if  
451 the ratio is greater than or equal to 1, then samples have amplified sufficiently. To

452 identify the exact score value for a qualitative QC metric, an ROC analysis was done on  
453 scores and the absolute truth (**Fig. S6**).

454

#### 455 Data Analysis for CRISPR-based SNP calling

456 Each well has a guide specific to the mutant or the wild-type SNP. The comparison is  
457 important to assign a genotypic call to the sample. The DETECTR<sup>®</sup> reactions across the  
458 plate are not comparable to each other. For this purpose, the endpoint fluorescence  
459 intensities are normalized in each well to its own minimum intensity. This term is called  
460 fluorescence yield. The fluorescence yield can be compared across wells in a plate  
461 under the assumption that each well will have a similar minimum fluorescence starting  
462 point. Irrespective of the highest levels of the fluorescence intensities observed across  
463 samples, the yield for a given target must ideally remain the same assuming that similar  
464 concentrations of samples/target are being compared. This aids in normalizing the  
465 signal and comparing replicates across the wells in the same plate.

$$466 \quad F_y = \max(F)/\min(F)$$

467 The wildtype and mutant target guides on NTC must ideally not show any change in  
468 intensity over time. The fluorescence yield for NTC must remain constant across  
469 replicates, plates and close to 1.

$$470 \quad F_y(\text{NTC}) = 1$$

471 On the contrary, if a sample has a fluorescence yield of 1, then it qualifies for a No Call.

472

#### 473 *General rules for variant calling*

474 1. NTC was assigned NTC



- 475 2. If the Contrast of the sample for a SNP was between minimum and maximum  
476 contrast for the plate, then the sample is assigned a NoCall.  
477 3. If the Size of the sample is lower than the Size of the NTC on the plate, then the  
478 sample is assigned a NoCall.

479 
$$C_{min}(NTC-snp) \leq C(sample-snp) \leq C_{max}(NTC-snp) \rightarrow \text{NoCall}$$

480 
$$S_{min}(NTC-snp) \leq S(sample-snp) \leq S_{max}(NTC-snp) \rightarrow \text{NoCall}$$

481 
$$\log_2(Fy(WT)) > \log_2(Fy(M)) \rightarrow \text{Wild Type}$$

482 
$$\log_2(Fy(WT)) < \log_2(Fy(M)) \rightarrow \text{Mutant}$$

483

#### 484 SNP Calls

485 We used the following procedure to evaluate the concordance between sequencing and  
486 DETECTR<sup>®</sup> technologies for genotypic classification of the clinical cohort dataset.  
487 First, we considered all samples and SNPs for which both sequencing and DETECTR<sup>®</sup>  
488 data was present in the distributed files by matching the SNP IDs and sample names.  
489 This included cleaning and curing the dataset which had failed LAMP reactions and  
490 identifying WT and MUT based on the spacer fluorescent. This yielded a preliminary  
491 data set containing 279 calls across three SNPs against 93 samples. After eliminating  
492 samples that had failed to amplify in the LAMP reaction but were assigned a genotype,  
493 the resulting final analysis data consisted of 272 calls (WT, MUT and NoCall) spread  
494 across three SNPs and 91 samples. For each of the three SNPs in the analysis data  
495 set, we identified and recorded both sequencing and DETECTR<sup>®</sup> genotypes (including  
496 NoCalls and LAMP Fails) for each of the 93 patients. The 91 patients include the  
497 individuals for whom actual sequencing data was available.

498

## 499 **Statistical analysis**

### 500 SNP Calls

501 For each SNP in the analysis, we computed a variety of statistics evaluating the  
502 concordance between genotype calls on the two different technologies. The concordant  
503 and discordant genotypes were visualized through contingency tables. For each SNP,  
504 there are three possible genotypes (WT, MUT and No Call). The concordance rates  
505 were calculated without the samples that failed the LAMP reaction (**Fig. 3B and Table**  
506 **S1**). The 2x2 cross tables classify all three SNPs across all the samples between  
507 sequencing and DETECTR<sup>®</sup> technologies (**Fig. 3B and Table S1**). The data  
508 transformation and statistical analysis was done in R (42).

509

## 510 **Acknowledgments**

511 We thank the UCSF Center for Advanced Technology core facility (Delsy  
512 Martinez and Tyler Miyasaki) for their efforts in high-throughput sequencing of viral  
513 cDNA libraries using the Illumina NovaSeq 6000 instrument, and Mary Kate Morris from  
514 the California Department of Public Health for providing the heat-inactivated viral  
515 cultures. We also thank Lucas Harrington and Teresa Peterson for their critical review of  
516 this manuscript.

517 This work has been funded by the Innovative Genomics Institute (IGI) at UC  
518 Berkeley and UC San Francisco (C.Y.C.), the Sandler Program for Breakthrough  
519 Biomedical Research (C.Y.C.), US Centers for Disease Control and Prevention contract  
520 75D30121C10991 (C.Y.C.), and Mammoth Biosciences.

521

522 **Author contributions**

523 C.L.F., J.S.C., and C.Y.C. conceived and designed the study. C.Y.C. and V.S.  
524 coordinated the SARS-CoV-2 whole-genome sequencing efforts and RT-LAMP primer  
525 design and testing. C.L.F., J.P.B., J.C., and J.S.C. designed guide RNAs for CRISPR-  
526 Cas12 testing. B.M., J.P.B., R.N.D., E.S., and C.G.H. tested guide RNAs and ran  
527 DETECTR<sup>®</sup> experiments. V.S., N.B., B.W., A.S.-G., K.R., J.S., S.M., and C.Y.C.  
528 collected samples. C.L.F., V.S., B.M., V.N., J.P.B., J.C., J.S.C., and C.Y.C. analyzed  
529 data. C.L.F., V.S., V.N., B.M., J.P.B., J.C., J.S.C., and C.Y.C. wrote the manuscript. All  
530 authors read the manuscript and agree to its contents.

531

532 **Competing interests**

533 C.Y.C. is the director of the UCSF-Abbott Viral Diagnostics and Discovery Center and  
534 receives research support from Abbott Laboratories, Inc. C.L.F., B.M., V.N., J.P.B.,  
535 R.N.D., E.S., C.G.H., J.C., and J.S.C. are employees of Mammoth Biosciences. C.Y.C.  
536 is a member of the scientific advisory board for Mammoth Biosciences. The other  
537 authors declare no competing interests.

538

539 **Data and Materials Availability**

540 All data needed to evaluate the conclusions in the paper are present in the paper and/or  
541 the Supplementary Materials. The CasDx1 protein can be provided by Mammoth  
542 Biosciences to the extent feasible, pending scientific review and a completed material


543 transfer agreement. Requests for the CasDx1 protein should be submitted to Janice

544 Chen at [janice@mammothbiosci.com](mailto:janice@mammothbiosci.com).

545

546 **Supplementary Figures**

547



548

549 **Fig. S1. DETECTR<sup>®</sup> curves from gene fragments and heat-inactivated viral**  
550 **cultures. (A)** Raw fluorescence curves from three Cas12 enzymes (CasDx1,  
551 LbCas12a, AsCas12a) complexed with WT and MUT SNP gRNAs run on PCR-  
552 amplified gene fragments representing WT and MUT SNP targets. **(B)** Raw  
553 fluorescence curves from three Cas12 enzymes (CasDx1, LbCas12a, AsCas12a) on  
554 eight heat-inactivated viral culture samples from various SARS-CoV-2 lineages, a no  
555 target control (RT-LAMP) and CasDx1 detection controls (WT, MUT and NTC). CasDx1  
556 replicates (n = 3),  $\pm 1.0SD$


557

558

559

560

561




562

563

**Fig. S2. Raw fluorescence RT-LAMP curves for each clinical sample. The raw**

564 fluorescence RT-LAMP amplification curves for each of the clinical samples analyzed (n  
565 = 3 replicates). Each line is representative of the median  $\pm 1.0SD$  of the three RT-LAMP  
566 replicates for each sample. RT-LAMP replicates that passed QC are represented in  
567 navy blue and failed LAMP replicates are shown in orange. Only valid RT-LAMP  
568 replicates were used in subsequent data analysis.



569  
570 **Fig. S3. Raw fluorescence CasDx1 curves for each clinical sample amplified by**  
571 **RT-LAMP.** Each clinical sample was amplified with RT-LAMP in triplicate, and the  
572 resulting amplicons were detected by CasDx1 in triplicate. The raw fluorescence curves  
573 show WT detection in blue and MUT detection in green. Each line is representative of  
574 the median  $\pm 1.0SD$  of the CasDx1 replicates (n = 3) for each WT and MUT guide for  
575 each of the RT-LAMP replicates (n = 3), represented by different patterned lines.


576

577

578

579

580



581

582 **Fig. S4. Evaluation of the DETECTR® data analysis pipeline and making final calls.**

583 (A) Allele discrimination plot visualizing the scaled signals from the COVID Variant

584 DETECTR® assay on gene fragments. The allele discrimination plots represent scatter

585 plots of scaled WT and MUT fluorescence values plotted against each other. (B)

586 Contrast-Size plots of the COVID Variant DETECTR® assay data on gene fragments to

587 decrease ambiguity of the scaled signals, a ratio of the WT and MUT transformed

588 values are plotted against the average of the WT and MUT transformed values on the

589 MA plot. (C) Allele discrimination plot visualizing the scaled signals from the COVID


590 Variant DETECTR® assay on clinical sample. (D) MA plots of the COVID Variant

591 DETECTR® assay on the gene fragments (n = 30 WT; n = 30 MUT for each SNP) and

592 no template controls (n = 33 WT; n = 33 MUT for each SNP) used to test the data

593 analysis.





594

595 **Fig. S5. Highly specific detection by CasDx1 for each SNP on RT-LAMP replicates**

596 **from clinical samples. (A) The DETECTR<sup>®</sup> assay workflow from LAMP amplification to**

597 **SNP identification. (B) Schematic showing the relationship between clinical samples,**


598 LAMP replicates and CasDx1 replicates that culminate in a final SNP call. (C) Heat map  
599 showing CasDx1 signal (n = 3) per every LAMP replicate (n = 3) for each SNP on every  
600 clinical sample reflecting samples prior to discordance testing.

601

602

603

604



605

606 **Fig. S6. Determination of RT-LAMP threshold with a ROC curve.**

607 Thresholds for LAMP quality analysis were derived to determine which samples had  
608 amplified sufficiently. The exact score value for this qualitative QC metric was  
609 determined using a ROC analysis.

610

611

612

613



614

615 **Fig. S7. Visualization of SNP calls by the DETECTR<sup>®</sup> data analysis pipeline.** Box  
616 plots of all the clinical samples illustrate the spread of the scaled signals for each of the  
617 samples across the replicates in the experiment. SNP calls were made on each sample  
618 agreement with the median values depicted on the box plot of the sample, which also  
619 provided an analytical confirmation of the DETECTR<sup>®</sup> results.

620


621

622

623

624

625



626

627

628 **Fig. S8. Clinical evaluation results with clinical samples of uncertain integrity. (A)**

629 Raw fluorescence CasDx1 curves for the clinical samples with discordant DETECTR<sup>®</sup>

630 and WGS results. WT detection is represented by blue lines and MUT detection is

631 represented by green lines. Each line is representative of the median  $\pm 1.0SD$  of the

632 CasDx1 replicates ( $n = 3$ ) for each guide for each of the LAMP replicates ( $n = 3$ ), and

633 each RT-LAMP replicate is represented by different patterned lines. (B) Visualization of

634 the COVID Variant DETECTR<sup>®</sup> and SARS-CoV-2 WGS assays showing the alignment

635 of final calls. Across all of the clinical samples in this cohort, 80 out of the 91 clinical

636 sample COVID Variant DETECTR<sup>®</sup> assay calls were consistent with the SARS-CoV-2

637 WGS calls. (C) Summary of re-testing of discordant samples from the original clinical

638 sample shows nearly all SNP discrepancies are resolved.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Patient sample	DETECTR (R)				Generic Lineage Classification	Whole Genome Sequencing					qPCR
	Name	SNP 452	SNP 484	SNP 501		SNP 452	SNP 484	SNP 501	Pango Lineage	Lineage/Variant Call	
COVID-01	WT	WT	WT		SARS-CoV-2	WT	WT	WT	B.1.1.519	N/A	16.2
COVID-02	WT	WT	WT		SARS-CoV-2	WT	WT	WT	B.1.1.222	N/A	17.2
* COVID-03	WT	WT	WT		SARS-CoV-2	WT	WT	WT	B.1.243	N/A	13.9
COVID-04	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.427	Epsilon	15.9
COVID-05	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.427	Epsilon	22.6
COVID-06	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.429	Epsilon	15.7
COVID-07	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.427	Epsilon	16.1
COVID-08	WT	WT	WT		SARS-CoV-2	WT	WT	WT	B.1.309	N/A	19.6
COVID-09	WT	WT	WT		SARS-CoV-2	WT	WT	WT	B.1.1.348	N/A	17.2
COVID-10	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.429	Epsilon	13.1
COVID-11	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	19.3
* COVID-12	WT	M	WT		Eta/Iota/Zeta	WT	M	WT	B.1.526	Iota	21.0
* COVID-13	M	WT	WT		Delta/Epsilon/Kappa	M	Q	WT	B.1.617.1	Kappa	17.3
COVID-14	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	14.9
COVID-15	WT	WT	WT		SARS-CoV-2	WT	WT	WT	B.1.575	N/A	18.4
COVID-16	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	21.6
COVID-17	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	13.2
COVID-18	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.280	N/A	13.9
COVID-19	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	18.9
* COVID-20	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	23.5
COVID-21	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	25.9
COVID-22	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	22.2
COVID-23	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	17.1
COVID-24	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	23.6
COVID-25	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	20.4
COVID-26	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	21.4
COVID-27	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	25.0
COVID-28	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	15.2
COVID-29	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	16.6
COVID-30	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	17.5
* COVID-31	WT	WT	M		Alpha	NoCall	WT	M	B.1.1.7	Alpha	23.6
COVID-32	WT	M	WT		Eta/Iota/Zeta	WT	M	WT	B.1.1.318	N/A	15.6
COVID-33	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	22.0
COVID-34	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	17.2
COVID-35	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	18.9
COVID-36	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	18.9
COVID-37	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	18.5
COVID-38	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	15.4
COVID-39	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	16.4
COVID-40	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	16.7
* COVID-41	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	24.2
COVID-42	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	17.7
COVID-43	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	15.3
COVID-44	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	17.9
COVID-45	WT	M	M		Beta/Gamma/Mu	WT	M	M	P1	Gamma	16.6
COVID-46	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	23.2
COVID-47	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.526.1	N/A	16.6
COVID-48	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	13.7
COVID-49	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	17.9
COVID-50	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	15.8
COVID-51	WT	WT	M		Alpha	WT	WT	M	B.1.1.7	Alpha	15.8
COVID-52	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	AY.1	Delta	18.1
COVID-53	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	AY.1	Delta	22.9
COVID-54	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	AY.1	Delta	22.0
COVID-55	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	19.4
* COVID-56	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	21.1
COVID-57	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.526.1	N/A	26.6
COVID-58	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	17.8
COVID-59	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	AY.1	Delta	18.5
COVID-60	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	AY.1	Delta	21.5
* COVID-61	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	16.9
COVID-62	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	14.1
* COVID-63	M	WT	WT		Delta/Epsilon/Kappa	M	Q	WT	B.1.617.2	Delta †	12.2
COVID-64	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	22.0
COVID-65	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	21.9
COVID-66	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	14.8
COVID-67	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	18.7
COVID-68	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	16.6
COVID-69	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	19.0
COVID-70	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	21.1
COVID-71	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	14.0
COVID-72	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	25.6
* COVID-73	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	21.7
COVID-74	WT	M	M		Beta/Gamma/Mu	WT	M	M	B.1.623	N/A	23.7
COVID-75	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	17.7
COVID-76	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	AY.1	Delta	20.5
COVID-77	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	25.2
COVID-78	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	18.7
COVID-79	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	19.3
COVID-80	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	18.4
* COVID-81	WT	M	M		Beta/Gamma/Mu	WT	M	M	B.1.621	Mu	19.2
COVID-82	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	AY.1	Delta	18.3
COVID-83	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	A.2.5	Delta	17.6
COVID-84	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	AY.1	Delta	12.7
COVID-85	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	21.0
COVID-86	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	16.8
COVID-87	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	17.7
COVID-88	WT	M	WT		Eta/Iota/Zeta	WT	M	WT	B.1.526	Iota	14.8
COVID-89	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	20.5
COVID-90	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	B.1.617.2	Delta	21.6
COVID-91	M	WT	WT		Delta/Epsilon/Kappa	M	WT	WT	A.2.5	Delta	15.6

640 **Table S1. Overall results summary of final SNP calls by the DETECTR<sup>®</sup> assay and**  
641 **viral WGS.** A summary table of the final SNP calls from the DETECTR<sup>®</sup> assay and the  
642 SARS-CoV-2 whole genome sequencing assay after discordant testing. The table  
643 includes the lineage classification from DETECTR<sup>®</sup> calls as well as the PANGO lineage  
644 and WHO labels assigned to the WGS calls. Ct values from running an FDA EUA  
645 authorized SARS-CoV-2 RT-PCR assay, the Taqpath™ COVID-19 RT-PCR kit, are  
646 shown. Discordant samples were reflexed back for reprocessing (\*); COVID-63 was  
647 classified as a Delta variant by WGS despite its Q484 SNP call. (†).  
648

Type	Name	Sequence	Source
Guide RNA	Dx1_L452	UAAUUUCUACUAAGUGUAGAUuaaacaaucauacagguaa	Dharmacon or Synthego
	Dx1_R452	UAAUUUCUACUAAGUGUAGAUccGguauagauuguuagga	Dharmacon or Synthego
	Dx1_E484	UAAUUUCUACUAAGUGUAGAUaaaccuuaacaccuuaca	Dharmacon or Synthego
	Dx1_K484	UAAUUUCUACUAAGUGUAGAUaaaccuuUaacaccuuaca	Dharmacon or Synthego
	Dx1_N501	UAAUUUCUACUAAGUGUAGAUcaaccacuaauggguugg	Dharmacon or Synthego
	Dx1_Y501	UAAUUUCUACUAAGUGUAGAUaaccUcuUauggguuggu	Dharmacon or Synthego
	AsCas12a_L452	UAAUUUCUACUCUUGUAGAUuaaacaaucauacagguaa	Dharmacon or Synthego
	AsCas12a_R452	UAAUUUCUACUCUUGUAGAUccGguauagauuguuagga	Dharmacon or Synthego
	AsCas12a_E484	UAAUUUCUACUCUUGUAGAUaaaccuuaacaccuuaca	Dharmacon or Synthego
	AsCas12a_K484	UAAUUUCUACUCUUGUAGAUaaaccuuUaacaccuuaca	Dharmacon or Synthego
	AsCas12a_N501	UAAUUUCUACUCUUGUAGAUcaaccacuaauggguugg	Dharmacon or Synthego
	AsCas12a_Y501	UAAUUUCUACUCUUGUAGAUaaccUcuUauggguuggu	Dharmacon or Synthego
Reporter	ssDNA reporter	/5Alex594N/TTATTATT/3IAbrRQSp/	IDT
Gene fragment	Mutant	tctgcttactaatgtctatgcagattcattgtaattagaggtgatgaagtcagacaaatcgctccag ggcaaaactggaaatattgctgattataataaaattaccagatgatttacaggctgcgttatagctt ggaattcaacaatcttgattctaaggttggtgtaattataattaccggtatagattgtaggaagctt aatcacaaccctttgagagagatatttcaactgaaatctatcaggccgtagcacaccttgaatg gtgtaaaggtttaattgtacttccittacaatcatatggtttccaaccactatggtggtggtacc aacatacacagtagtagtactttctttgaactctacatgca	Twist Biosciences
	Wild Type	tctgcttactaatgtctatgcagattcattgtaattagaggtgatgaagtcagacaaatcgctccag ggcaaaactggaaagattgctgattataataaaattaccagatgatttacaggctgcgttatagctt ggaattcaacaatcttgattctaaggttggtgtaattataattaccggtatagattgtaggaagctt aatcacaaccctttgagagagatatttcaactgaaatctatcaggccgtagcacaccttgaatg gtgtaaaggtttaattgtacttccittacaatcatatggtttccaaccactatggtggtggtacc aacatacacagtagtagtactttctttgaactctacatgca	Twist Biosciences
LAMP Primer	set1-F3	CAAACCTGGAAGATTGCTGA	Eurofins Genomics
	set1-B3	TACTACTACTCTGTATGGTTG	Eurofins Genomics
	set1-BIP	CCACCAACCTTAGAATCAAGATTGTTAAATTACCAGATGATTTTACAGGC	Eurofins Genomics
	set1-FIP	TCAACTGAAATCTATCAGGCCGGGAAACCATATGATTGTTAAAGGAA	Eurofins Genomics
	set1-LF	TAGAATCCAAGCTATAACGCA	Eurofins Genomics
	set1-LB	TAGCACACCTTGAATGGTG	Eurofins Genomics
	set2-F3	TTCTAAGGTTGGTGGTAATTATAATTA	Eurofins Genomics
	set2-B3	CATTGAAGTTGAAATTGACACAT	Eurofins Genomics
	set2-BIP	TGGGTTGGAACCATATGATTGTTAAATCTATCAGGCCGGTAGC	Eurofins Genomics
	set2-FIP	TGTTGGTTACCAACCATACAGAGTAAGACTTTTTAGGTCCACAAACA	Eurofins Genomics
	set2-LF	GTAAGGAAAGTAAACAATTAACCT	Eurofins Genomics
	set2-LB	AACTTCTACATGCACCAGCAA	Eurofins Genomics

649

650 **Table S2. Nucleic acid sequences used in this study.** A list of guide RNAs, reporter

651 molecules, LAMP primers and synthetic gene fragment targets with their respective

652 suppliers.

653

654 **REFERENCES**

655

- 656 1. S. P. Otto *et al.*, The origins and potential future of SARS-CoV-2 variants of  
657 concern in the evolving COVID-19 pandemic. *Curr Biol* **31**, R918-R929 (2021).
- 658 2. R. P. Walensky, H. T. Walke, A. S. Fauci, SARS-CoV-2 Variants of Concern in  
659 the United States-Challenges and Opportunities. *JAMA* **325**, 1037-1038 (2021).
- 660 3. X. Deng *et al.*, Genomic surveillance reveals multiple introductions of SARS-  
661 CoV-2 into Northern California. *Science* **369**, 582-587 (2020).
- 662 4. S. Truelove *et al.*, Projected resurgence of COVID-19 in the United States in  
663 July-December 2021 resulting from the increased transmissibility of the Delta  
664 variant and faltering vaccination. *medRxiv*, (2021).
- 665 5. N. L. Washington *et al.*, Emergence and rapid transmission of SARS-CoV-2  
666 B.1.1.7 in the United States. *Cell* **184**, 2587-2594 e2587 (2021).
- 667 6. M. Okereke, Spread of the delta coronavirus variant: Africa must be on watch.  
668 *Public Health Pract (Oxf)* **2**, 100209 (2021).
- 669 7. E. C. Sabino *et al.*, Resurgence of COVID-19 in Manaus, Brazil, despite high  
670 seroprevalence. *Lancet* **397**, 452-455 (2021).
- 671 8. V. Servellita *et al.*, Predominance of antibody-resistant SARS-CoV-2 variants in  
672 vaccine breakthrough cases from the San Francisco Bay Area, California.  
673 *medRxiv*, (2021).
- 674 9. T. Kustin *et al.*, Evidence for increased breakthrough rates of SARS-CoV-2  
675 variants of concern in BNT162b2-mRNA-vaccinated individuals. *Nat Med*,  
676 (2021).
- 677 10. J. Jung, H. Sung, S. H. Kim, Covid-19 Breakthrough Infections in Vaccinated  
678 Health Care Workers. *N Engl J Med* **385**, 1629-1630 (2021).
- 679 11. C. M. Brown *et al.*, Outbreak of SARS-CoV-2 Infections, Including COVID-19  
680 Vaccine Breakthrough Infections, Associated with Large Public Gatherings -  
681 Barnstable County, Massachusetts, July 2021. *MMWR Morb Mortal Wkly Rep*  
682 **70**, 1059-1062 (2021).
- 683 12. F. Campbell *et al.*, Increased transmissibility and global spread of SARS-CoV-2  
684 variants of concern as at June 2021. *Euro Surveill* **26**, (2021).
- 685 13. W. T. Harvey *et al.*, SARS-CoV-2 variants, spike mutations and immune escape.  
686 *Nat Rev Microbiol* **19**, 409-424 (2021).
- 687 14. W. F. Garcia-Beltran *et al.*, Multiple SARS-CoV-2 variants escape neutralization  
688 by vaccine-induced humoral immunity. *Cell* **184**, 2523 (2021).
- 689 15. D. Focosi, M. Tuccori, A. Baj, F. Maggi, SARS-CoV-2 Variants: A Synopsis of In  
690 Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and  
691 Monoclonal Antibodies. *Viruses* **13**, (2021).



- 692 16. B. B. Oude Munnink *et al.*, The next phase of SARS-CoV-2 surveillance: real-  
693 time molecular epidemiology. *Nat Med* **27**, 1518-1524 (2021).
- 694 17. RockefellerFoundation, "Implementation Framework: Toward a National Genomic  
695 Surveillance Network," (Rockefeller Foundation, New York, 2021).
- 696 18. M. S. Verosloff *et al.*, CRISPR-Cas enzymes: The toolkit revolutionizing  
697 diagnostics. *Biotechnol J*, e2100304 (2021).
- 698 19. J. P. Broughton *et al.*, CRISPR-Cas12-based detection of SARS-CoV-2. *Nat*  
699 *Biotechnol* **38**, 870-874 (2020).
- 700 20. H. de Puig *et al.*, Minimally instrumented SHERLOCK (miSHERLOCK) for  
701 CRISPR-based point-of-care diagnosis of SARS-CoV-2 and emerging variants.  
702 *Sci Adv* **7**, (2021).
- 703 21. M. Patchsung *et al.*, Clinical validation of a Cas13-based assay for the detection  
704 of SARS-CoV-2 RNA. *Nat Biomed Eng* **4**, 1140-1149 (2020).
- 705 22. P. Fozouni *et al.*, Amplification-free detection of SARS-CoV-2 with CRISPR-  
706 Cas13a and mobile phone microscopy. *Cell* **184**, 323-333 e329 (2021).
- 707 23. FDA. SARS-CoV-2 RNA DETECTR Assay, (2020),  
708 <https://www.fda.gov/media/139937/download>, date accessed: November 14,  
709 2021.
- 710 24. FDA. Sherlock™ CRISPR SARS-CoV-2 kit, (2020),  
711 <https://www.fda.gov/media/137748/download>, date accessed: November 14,  
712 2021.
- 713 25. J. S. Gootenberg *et al.*, Multiplexed and portable nucleic acid detection platform  
714 with Cas13, Cas12a, and Csm6. *Science* **360**, 439-444 (2018).
- 715 26. C. Chiu, Cutting-Edge Infectious Disease Diagnostics with CRISPR. *Cell Host*  
716 *Microbe* **23**, 702-704 (2018).
- 717 27. L. Zhang *et al.*, Ten emerging SARS-CoV-2 spike variants exhibit variable  
718 infectivity, animal tropism, and antibody neutralization. *Commun Biol* **4**, 1196  
719 (2021).
- 720 28. K. S. Corbett *et al.*, SARS-CoV-2 mRNA vaccine design enabled by prototype  
721 pathogen preparedness. *Nature* **586**, 567-571 (2020).
- 722 29. F. P. Polack *et al.*, Safety and Efficacy of the BNT162b2 mRNA Covid-19  
723 Vaccine. *N Engl J Med* **383**, 2603-2615 (2020).
- 724 30. R. Bos *et al.*, Ad26 vector-based COVID-19 vaccine encoding a prefusion-  
725 stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular  
726 immune responses. *NPJ Vaccines* **5**, 91 (2020).
- 727 31. F. Konings *et al.*, SARS-CoV-2 Variants of Interest and Concern naming scheme  
728 conducive for global discourse. *Nat Microbiol* **6**, 821-823 (2021).
- 729 32. F. de Mello Malta *et al.*, Mass molecular testing for COVID19 using NGS-based  
730 technology and a highly scalable workflow. *Sci Rep* **11**, 7122 (2021).

- 731 33. Z. Igloi *et al.*, Clinical Evaluation of Roche SD Biosensor Rapid Antigen Test for  
732 SARS-CoV-2 in Municipal Health Service Testing Site, the Netherlands. *Emerg*  
733 *Infect Dis* **27**, 1323-1329 (2021).
- 734 34. C. Broccanello *et al.*, Comparison of three PCR-based assays for SNP  
735 genotyping in plants. *Plant Methods* **14**, 28 (2018).
- 736 35. F. E. McGuigan, S. H. Ralston, Single nucleotide polymorphism detection: allelic  
737 discrimination using TaqMan. *Psychiatr Genet* **12**, 133-136 (2002).
- 738 36. J. Singh, P. Pandit, A. G. McArthur, A. Banerjee, K. Mossman, Evolutionary  
739 trajectory of SARS-CoV-2 and emerging variants. *Virology* **18**, 166 (2021).
- 740 37. J. Arizti-Sanz *et al.*, Equipment-free detection of SARS-CoV-2 and Variants of  
741 Concern using Cas13. *medRxiv*, (2021).
- 742 38. W. A. Kibbe, OligoCalc: an online oligonucleotide properties calculator. *Nucleic*  
743 *Acids Res* **35**, W43-46 (2007).
- 744 39. J. Quick *et al.*, Multiplex PCR method for MinION and Illumina sequencing of  
745 Zika and other virus genomes directly from clinical samples. *Nat Protoc* **12**, 1261-  
746 1276 (2017).
- 747 40. A. O'Toole *et al.*, Assignment of epidemiological lineages in an emerging  
748 pandemic using the pangolin tool. *Virus Evol* **7**, veab064 (2021).
- 749 41. A. Rambaut *et al.*, A dynamic nomenclature proposal for SARS-CoV-2 lineages  
750 to assist genomic epidemiology. *Nat Microbiol* **5**, 1403-1407 (2020).
- 751 42. R\_Core\_Team. R: A Language and Environmental for Statistical Computing,  
752 (Vienna, Austria, 2018), <https://www.R-project.org>, date accessed: 11/26/21.  
753